The influence of drug-like concepts on decision-making in medicinal chemistry
The DOI matches its Crossref record; 59 of the 60 references it cites were found in a registry or an index.
Abstract
The application of guidelines linked to the concept of drug-likeness, such as the 'rule of five', has gained wide acceptance as an approach to reduce attrition in drug discovery and development. However, despite this acceptance, analysis of recent trends reveals that the physical properties of molecules that are currently being synthesized in leading drug discovery companies differ significantly from those of recently discovered oral drugs and compounds in clinical development. The consequences of the marked increase in lipophilicity--the most important drug-like physical property--include a greater likelihood of lack of selectivity and attrition in drug development. Tackling the threat of compound-related toxicological attrition needs to move to the mainstream of medicinal chemistry decision-making.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“(Note that liophilicity per se may not be relevant, as drugs require carriers to cross membranes [18], and promiscuity and off-target effects increase with lipophilicity [1679].)”
From Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases (2009) · cites this paper as [1679]
Citations
Cites
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00129-0 · Cited by 18,139
Lipinski, C. A., Lombardo, F., Dominy, B. W., & Feeney, P. J. (1997) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(96)00423-1 · Cited by 11,385
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“Overall oral bioavailability depends not just on absorption but also on dissolution, gut transit time and first-pass metabolism, so it is perhaps surprising that rat bioavailability can be categorized by simple physical properties such as PSA and rotatable bond”
BackgroundLead- and drug-like compounds: the rule-of-five revolution
Lipinski, C. A. (2004) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2004.11.007 · Cited by 6,199 · cited 1×
“jpg" NDATA ITEM> ]> Ten years have passed since the publication of the 'rule of five' physical property guidelines for drug permeabilit”
BackgroundCan the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Budavari, S. (1998) · Royal Society of Chemistry eBooks · Cited by 2,741
ADMET in silico modelling: towards prediction paradise?
van de Waterbeemd, H., & Gifford, E. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1032 · Cited by 1,863
Martin, Y. C. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm0492002 · Cited by 1,020 · cited 1×
“, and number of rule-of-five violations, PSA and ionization stat”
BackgroundQuantitative approach to biochemical structure-activity relationships
Hansch, C. (1969) · Accounts of Chemical Research · doi:10.1021/ar50020a002 · Cited by 918 · cited 1×
“This is not surprising: the role of LogP in influencing drug potency, pharmacokinetics and toxicity has been established for many year”
BackgroundMolecular Complexity and Its Impact on the Probability of Finding Leads for Drug Discovery
Hann, M. M., Leach, A. R., & Harper, G. (2001) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci000403i · Cited by 877 · cited 1×
“This allows the processes of chemical optimization, which frequently increase physical propertie”
Background
Research works printed but not linked: 3
- Kubinyi, H. Lipophilicity and biological activity. Drug transport and drug distribution in model systems and in biological systems. Arzn. Forsch. 29, 1067–1080 (1979).
- Wood, A. Annual Reports in Medicinal Chemistry Volume 41 503–522 (Academic Press, Burlington, 2006).
- Gray, N. Changing Landscapes: A Special Report on the World's Top 50 Pharma Companies. Pharmaceutical Executive web site [online] , (2006)
Cited by
Items 901–1,000 of 1,006
Monteleone, S., Fuchs, J. E., & Liedl, K. R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00552 · Cited by 29
“A criterion favoring complex 3D shapes, with chiral centers and high sp3 carbon contents, low number of double bonds and fused aromatic rings, in candidate molecules might complement widely accepted criteria for drug-likeness solely based on 2D molecular properties, like solubility and MW (Lipinski, 2004; Leeson and S…”
BackgroundJanus Kinase Antagonists and Other Novel Small Molecules for the Treatment of Crohn's Disease
Boland, B. S., & Vermeire, S. (2017) · Gastroenterology Clinics of North America · doi:10.1016/j.gtc.2017.05.015 · Cited by 38
Protein degradation: a validated therapeutic strategy with exciting prospects
Lebraud, H., & Heightman, T. D. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170030 · Cited by 29
İçsel, C., Yılmaz, V. T., Cevatemre, B., Aygün, M., & Ulukaya, E. (2019) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2019.03.008 · Cited by 30
Phenylthiazoles with nitrogenous side chain: An approach to overcome molecular obesity
Elsebaei, M. M., Abutaleb, N. S., Mahgoub, A. A., Li, D., Hagras, M., Mohammad, H. T., Seleem, M. N., & Mayhoub, A. S. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111593 · Cited by 33
Practical approaches to evaluating and optimizing brain exposure in early drug discovery
Freeman, B. B., Yang, L., & Ranković, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111643 · Cited by 34
Application of Negative Design To Design a More Desirable Virtual Screening Library
Yang, Z., He, J.-H., Lü, A., Hou, T., & Cao, D. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01476 · Cited by 33
Lorthiois, E., Roache, J., Barnes‐Seeman, D., Altmann, E., Hassiepen, U., Turner, G. M., Duvadie, R., Horn̆ák, V., Karki, R. G., Schiering, N., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00279 · Cited by 29
What’s in a Name? Drug Nomenclature and Medicinal Chemistry Trends using INN Publications
Serafini, M. T., Cargnin, S., Massarotti, A., Tron, G. C., Pirali, T., & Genazzani, A. A. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00181 · Cited by 33
Kundu, B., Raychaudhuri, D., Mukherjee, A., Sinha, B. P., Sarkar, D., Bandopadhyay, P., Pal, S., Das, N., Dey, D., Ramarao, K., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00532 · Cited by 30
Discovery of MK-4688 : an Efficient Inhibitor of the HDM2–p53 Protein–Protein Interaction
Reutershan, M. H., Machacek, M. R., Altman, M. D., Bogen, S. L., Cai, M., Cammarano, C., Chen, D., Christopher, M., Cryan, J. G., Daublain, P., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01524 · Cited by 31
Hussain, R., Shah, M., Iqbal, S., Rehman, W. U., Khan, S., Rasheed, L., Naz, H., Al-Ghulikah, H., Elkaeed, E. B., Pashameah, R. A., et al. (2022) · Frontiers in Chemistry · doi:10.3389/fchem.2022.1023316 · Cited by 29
“It was reported that numerous marketed drugs hold heteroarenes as the core center in their structure (Leeson and Springthorpe, 2007).”
BackgroundDavie, R. L., Edwards, H. J., Evans, D. M., Hodgson, S. T., Stocks, M. J., Smith, A. J., Rushbrooke, L. J., Pethen, S. J., Roe, M. B., Clark, D. E., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00921 · Cited by 32
In silico fragment-based drug design
Konteatis, Z. D. (2010) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2010.523697 · Cited by 33
“Lipophilic LE has been introduced as a way of monitoring how efficiently lipo-philicity is managed during lead optimization [45] .”
BackgroundTai, V. W. ‐., Garrido, D. M., Price, D. J., Maynard, A. T., Pouliot, J. J., Xiong, Z. Z., Seal, J. W., Creech, K. L., Kryn, L. H., Baughman, T. M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.080 · Cited by 29
Putz, M. V., & Dudaş, N. A. (2013) · Structural Chemistry · doi:10.1007/s11224-013-0249-6 · Cited by 30
Chambers, L. J., Stevens, A. J., Moses, A. P., Michel, A. D., Walter, D. S., Davies, D. J., Livermore, D. G., Fonfría, E., Demont, E. H., Vimal, M., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.03.096 · Cited by 36
Whitlock, G. A., Fish, P. V., Fray, M. J., Stobie, A., & Wakenhut, F. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.082 · Cited by 29
Callis, R. J., Rabow, A. A., Tonge, M. E., Bradbury, R. H., Challinor, M., Roberts, K., Jones, K. L., & Walker, G. E. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115580298 · Cited by 31
Cytotoxic compounds from Laurencia pacifica
Zaleta-Pinet, D. A., Holland, I., Muñoz‐Ochoa, M., Murillo-Álvarez, J. I., Sakoff, J. A., van Altena, I. A., & McCluskey, A. (2014) · Organic and Medicinal Chemistry Letters · doi:10.1186/s13588-014-0008-8 · Cited by 29
“Given the low molecular weights and high Fsp(3) content, the structure activity data elucidated in this small subset of analogues, we believe that 1 and 4 represent excellent leads for the development of selective and potent anticancer agents [31].”
BackgroundA Focused Screen Identifies Antifolates with Activity on Mycobacterium tuberculosis
Kumar, A., Guardia, A., Colmenarejo, G., Pérez‐Herrán, E., González, R. R., Torres, P. A., Calvo, D., Gómez, R. M., Ortega, F., Jiménez, E., et al. (2015) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5b00063 · Cited by 32
Watanabe, M., Kasai, M., Tomizawa, H., Aoki, M., Eiho, K., Isobe, Y., & Asano, S. (2014) · ACS Medicinal Chemistry Letters · doi:10.1021/ml5003184 · Cited by 29
Kenney, I. M., Beckstein, O., & Iorga, B. I. (2016) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-016-9949-5 · Cited by 29
Predicting Oral Druglikeness by Iterative Stochastic Elimination
Rayan, A., Marcus, D., & Goldblum, A. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci9004354 · Cited by 29
Fish, P. V., Deur, C., Gan, X., Greene, K. L., Hoople, D. W. T., MacKenny, M., Para, K. S., Reeves, K. A., Ryckmans, T., Stiff, C. M., et al. (2008) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.03.050 · Cited by 29
The current impact of water thermodynamics for small-molecule drug discovery
Geschwindner, S., & Ulander, J. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2019.1664468 · Cited by 30
Kamble, A. N. S., & Mitkar, A. A. (2023) · Journal of Pharmacognosy and Phytochemistry · doi:10.22271/phyto.2023.v12.i5d.14745 · Cited by 28
The contribution of physicochemical properties to multiple in vitro cytotoxicity endpoints
Lu, S., Jessen, B. A., Strock, C., & Will, Y. (2012) · Toxicology in Vitro · doi:10.1016/j.tiv.2012.01.025 · Cited by 28
Identification of tertiary sulfonamides as RORc inverse agonists
Fauber, B. P., René, O., Burton, B., Everett, C., Gobbi, A., Hawkins, J., Johnson, A. R., Liimatta, M. B., Lockey, P. M., Norman, M., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.03.038 · Cited by 29
Chen, H., Wang, C. Z., Ding, C., Wild, C., Copits, B. A., Swanson, G. T., Johnson, K. M., & Zhou, J. (2012) · ChemMedChem · doi:10.1002/cmdc.201200554 · Cited by 29
Concise and efficient one-pot copper-catalyzed synthesis of H-pyrazolo[5,1-a]isoquinolines
Yang, X., Luo, Y., Jin, Y., Liu, H., Jiang, Y., & Fu, H. (2012) · RSC Advances · doi:10.1039/c2ra21305b · Cited by 28
Trisciuzzi, D., Nicolotti, O., Miteva, M. A., & Villoutreix, B. O. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.11.013 · Cited by 28
Serendipitous Synthesis of Pyridoquinazolinones via an Oxidative C–C Bond Cleavage
Brendel, M., Sakhare, P. R., Dahiya, G., Subramanian, P., & Kaliappan, K. P. (2020) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.0c00982 · Cited by 28
Vekariya, R. H., Lei, W., Ray, A., Saini, S. K., Zhang, S., Molnar, G., Barlow, D. J., Karlage, K. L., Bilsky, E. J., Houseknecht, K. L., et al. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00503 · Cited by 28
Mrani, S. A., Аrrousse, N., Haldhar, R., Lahcen, A. A., Amine, A., Saffaj, T., Kim, S., & Taleb, M. (2022) · Lubricants · doi:10.3390/lubricants10030043 · Cited by 28
West, M. S., Gabbey, A. L., Huestis, M. P., & Rousseaux, S. A. L. (2022) · Organic Letters · doi:10.1021/acs.orglett.2c03570 · Cited by 28
Cheminformatics-Based Study Identifies Potential Ebola VP40 Inhibitors
Broni, E., Ashley, C. N., Adams, J., Manu, H., Aikins, E., Okom, M., Miller, W. A., Wilson, M. D., & Kwofie, S. K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076298 · Cited by 29
Shultz, M. D., Majumdar, D., Chin, D. N., Fortin, P. D., Feng, Y., Gould, T. A., Kirby, C. A., Stams, T., Waters, N. J., & Shao, W. (2013) · Journal of Medicinal Chemistry · doi:10.1021/jm400826j · Cited by 28
Chae, E., Shin, Y., Ryu, E.-J., Ji, M. K., Cho, N. R., Lee, K., Jeong, H. J., Kim, S.-J., Choi, Y., Oh, K. S., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.01.116 · Cited by 28
Sukerkar, P. A., MacRenaris, K. W., Meade, T. J., & Burdette, J. E. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200219e · Cited by 30
Hornberger, K. R., Chen, X., Crew, A. P. A., Kleinberg, A., Ma, L., Mulvihill, M. J., Wang, J., Wilde, V. L., Albertella, M. R., Bittner, M., et al. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.06.054 · Cited by 28
Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors
Scheiper, B., Matter, H., Steinhagen, H., Böcskei, Z., Fleury, V., & McCort, G. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.114 · Cited by 28
Structure-based drug design of chromone antagonists of the adenosine A 2A receptor
Andrews, S. P., Mason, J. S., Hurrell, E., & Congreve, M. (2014) · MedChemComm · doi:10.1039/c3md00338h · Cited by 28
Shamovsky, I. L., de Graaf, C., Alderin, L., Bengtsson, M., Bladh, H., Börjesson, L., Connolly, S., Dyke, H. J., van den Heuvel, M., Johansson, H., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900713y · Cited by 30
The mycotoxin definition reconsidered towards fungal cyclic depsipeptides
Taevernier, L., Wynendaele, E., VREESE, L. D., Burvenich, C., & Spiegeleer, B. M. J. D. (2016) · Journal of Environmental Science and Health Part C · doi:10.1080/10590501.2016.1164561 · Cited by 31
No Denying It: Medicinal Chemistry Training Is in Big Trouble
Rafferty, M. F. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00741 · Cited by 29
Lan, P., Romero, F. A., Wódka, D., Kassick, A. J., Dang, Q., Gibson, T., Cashion, D. K., Zhou, G., Chen, Y., Zhang, X., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01344 · Cited by 28
Attrition in the Pharmaceutical Industry: Reasons, Implications, and Pathways Forward
Alex, A., Smith, D. A., & Harris, C. (2015) · Wiley eBooks · doi:10.1002/9781118819586 · Cited by 28
Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds
Matter, H., Scheiper, B., Steinhagen, H., Böcskei, Z., Fleury, V., & McCort, G. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.112 · Cited by 28
Ligand Efficiency Metrics: Why All the Fuss?
Reynolds, C. H. (2015) · Future Medicinal Chemistry · doi:10.4155/fmc.15.70 · Cited by 31
Demont, E. H., Andrews, B. I., Bit, R. A., Campbell, C. A., Cooke, J. W. B., Deeks, N. J., Desai, S. D., Dowell, S. J., Gaskin, P., Gray, J. R., et al. (2011) · ACS Medicinal Chemistry Letters · doi:10.1021/ml2000214 · Cited by 27
Conn, P. M., Smithson, D. C., Hodder, P., Stewart, M. D., Behringer, R. R., Smith, E. W., Ulloa‐Aguirre, A., & Janovick, J. A. (2013) · Pharmacological Research · doi:10.1016/j.phrs.2013.12.004 · Cited by 28
Discovery of TAK-272: A Novel, Potent, and Orally Active Renin Inhibitor
Imaeda, Y., Tokuhara, H., Fukase, Y., Kanagawa, R., Kajimoto, Y., Kusumoto, K., Kondo, M., Snell, G., Behnke, C. A., & Kuroita, T. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00251 · Cited by 27
Devine, W. G., Thomas, S. M., Erath, J., Bachovchin, K. A., Lee, P. J., Leed, S. E., Rodrı́guez, A., Sciotti, R. J., Mensa‐Wilmot, K., & Pollastri, M. P. (2017) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.7b00011 · Cited by 27
Tavani, C., Bianchi, L., Palma, A. D., Passeri, G. I., Punzi, G., Pierri, C. L., Lovece, A., Cavalluzzi, M. M., Franchini, C., Lentini, G., et al. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.07.068 · Cited by 29
Elgaher, W. A. M., Hamed, M. M., Baumann, S., Herrmann, J. E., Siebenbürger, L., Krull, J., Cirnski, K., Kirschning, A., Brönstrup, M., Müller, R., et al. (2020) · Chemistry - A European Journal · doi:10.1002/chem.202000117 · Cited by 27
Salim, R., Hajib, S., Haldhar, R., Аrrousse, N., Kim, S., Ech-chihbi, E., AlObaid, A. A., Alami, A., & Taleb, M. (2023) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2023.137209 · Cited by 27
Parkinson, T., & Pryde, D. C. (2010) · Future Medicinal Chemistry · doi:10.4155/fmc.10.195 · Cited by 27
Beswick, P., Billinton, A., Chambers, L. J., Dean, D. K., Fonfría, E., Gleave, R. J., Medhurst, S. J., Michel, A. D., Moses, A. P., Patel, S., et al. (2010) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2010.05.107 · Cited by 27
García‐Sosa, A. T., Sild, S., Takkis, K., & Maran, U. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200203h · Cited by 29
Nowak, P., Cole, D. C., AULABAUGH, A. E., Bard, J., Chopra, R., Cowling, R. A., Fan, K. Y., Hu, B., Jacobsen, S. J., Jani, M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.11.052 · Cited by 27
Discovery of small molecule human C5a receptor antagonists
Sanganee, H. J., Baxter, A., Barber, S., Brown, A., Grice, D., Hunt, F., King, S. J., Laughton, D. L., Pairaudeau, G., Thong, B., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2008.12.104 · Cited by 27
Andrews, S. P., & Tehan, B. G. (2012) · MedChemComm · doi:10.1039/c2md20164j · Cited by 27
Ali, A. M., Gómez‐Biagi, R. F., Rosa, D. A., Lai, P., Heaton, W. L., Park, J. S., Eiring, A. M., Vellore, N. A., de Araujo, E. D., Ball, D. P., et al. (2016) · ChemMedChem · doi:10.1002/cmdc.201600021 · Cited by 29
Design, synthesis and cytotoxic activities of novel 2,5-diketopiperazine derivatives
Liao, S., Qin, X., Wang, Z., Li, D., Xu, L., Li, J., Tu, Z., & Liu, Y. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.06.002 · Cited by 27
“9) well consistent with the rule-of-5 of drug-likeness [33,34], which indicated that compounds 3aeg had good absorption and permeability, and could reach the target easily [33], thus resulting in their high activity.”
BackgroundTerakado, M., Suzuki, H., Hashimura, K., Tanaka, M., Ueda, H., Kohno, H., Fujimoto, T., Saga, H., Nakade, S., Habashita, H., et al. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00225 · Cited by 27
Grixti, J. M., O’Hagan, S., Day, P. J., & Kell, D. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00155 · Cited by 27
“increasing “molecular obesity” (Hann, 2011; Meanwell, 2011) that is seen in some cases as inimical to the finding of successful drugs (Leeson and Springthorpe, 2007; Leeson and Empfield, 2010).”
BackgroundHuang, J., Deng, X., Zhou, S., Wang, N., Qin, Y., Meng, L., Li, G., Xiong, Y., Fan, Y., Guo, L., et al. (2019) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2019.01.001 · Cited by 27
Atkinson, B. N., Steadman, D., Zhao, Y., Sipthorp, J., Vecchia, L., Ruza, R. R., Jeganathan, F., Lines, G., Frew, S., Monaghan, A. E., et al. (2019) · MedChemComm · doi:10.1039/c9md00096h · Cited by 27
Multi-Parameter Optimization: Identifying High Quality Compounds with a Balance of Properties
Segall, M. (2012) · Current Drug Metabolism · doi:10.2174/138920012799362864 · Cited by 27
Sarnpitak, P., Mujumdar, P., Taylor, P., Cross, M., Coster, M. J., Gorse, A., Krasavin, M., & Hofmann, A. (2015) · Biotechnology Advances · doi:10.1016/j.biotechadv.2015.05.006 · Cited by 27
Bengtsson, C., Blaho, S., Saitton, D. B., Brickmann, K., Broddefalk, J., Davidsson, Ö., Drmota, T., Folmer, R. H. A., Hallberg, K., Hallén, S., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.04.014 · Cited by 27
Castilho, M. S., Postigo, M. P., Pereira, H. M., Oliva, G., & Andricopulo, A. D. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.01.022 · Cited by 27
Lüthy, M., Wheldon, M. C., Haji-Cheteh, C., Atobe, M., Bond, P. S., O’Brien, P., Hubbard, R. E., & Fairlamb, I. J. S. (2015) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2015.04.005 · Cited by 26
A combinatorial approach for the discovery of drug-like inhibitors of 15-lipoxygenase-1
van der Vlag, R., Guo, H., Hapko, U., Eleftheriadis, N., Monjas, L., Dekker, F. J., & Hirsch, A. K. H. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.021 · Cited by 27
Youssef, E., El-Moneim, M. A. A., Fathalla, W., & Nafie, M. S. (2020) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-020-01947-6 · Cited by 26
Anizadeh, M. R., Zolfigol, M. A., Yarie, M., Torabi, M., & Azizian, S. (2020) · Research on Chemical Intermediates · doi:10.1007/s11164-020-04183-y · Cited by 26
Mei, W., Kong, Y., & Yan, G. (2021) · Organic Chemistry Frontiers · doi:10.1039/d1qo00775k · Cited by 26
Moussaoui, M., Baassi, M., Baammi, S., Soufi, H., Salah, M., Daoud, R., Allali, A. E., Belghiti, M. E., & Belaaouad, S. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2212304 · Cited by 26
“Cytochrome P450s (CYPs) include a superfamily of haem-con-taining proteins that are predominantly expressed in the liver and catalyse the metabolism of a broad range of exogenous and endogenous molecules (Leeson & Springthorpe, 2007; Hill & Young, 2010).”
BackgroundDiscovery and Optimization of the First ATP Competitive Type-III c-MET Inhibitor
Michaelides, I. N., Collie, G. W., Börjesson, U., Vasalou, C., Alkhatib, O., Barlind, L., Cheung, T., Dale, I. L., Embrey, K. J., Hennessy, E. J., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00401 · Cited by 26
Visible light mediated metal free photocatalytic synthesis of 2,4- disubstituted quinoline
Tivari, S., Beg, M. Z., Kashyap, A., Singh, P. K., Singh, P. P., Gahtori, P., & Srivastava, V. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101249 · Cited by 26
Babbe, H., Sundberg, T. B., Tichenor, M. S., Seierstad, M. J., Bacani, G. M., Berstler, J., Chai, W., Chang, L., Chung, D. M., Coe, K. J., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2307086120 · Cited by 27
Lohitha, N., Kumar, P. H., Sarveswari, S., Rathod, S., Chaudhari, S. Y., Tamboli, Y., Islam, I., & Vijayakumar, V. (2024) · ACS Omega · doi:10.1021/acsomega.4c00079 · Cited by 26
Advancing the activity cliff concept, part II
Stumpfe, D., de León, A. D. L. V., Dimova, D., & Bajorath, J. (2014) · F1000Research · doi:10.12688/f1000research.3788.1 · Cited by 27
Anaplastic lymphoma kinase (ALK) inhibitors: a review of design and discovery
Wang, W.-C., Shiao, H., Lee, C., Fung, K.-S., & Hsieh, H. (2014) · MedChemComm · doi:10.1039/c4md00048j · Cited by 29
Discovery of Benzimidazole CYP11B2 Inhibitors with in Vivo Activity in Rhesus Monkeys
Hoyt, S. B., Park, M. K., London, C., Xiong, Y., Tata, J., Bennett, D. J., Cooke, A., Cai, J., Carswell, E. L., Robinson, J., et al. (2015) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5b00054 · Cited by 26
Cox, J. M., Chu, H. D., Yang, C., Shen, H. C., Wu, Z., Balsells, J., Crespo, A., Brown, P. N., Zamlynny, B., Wiltsie, J., et al. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.02.057 · Cited by 26
Application of drug efficiency index in drug discovery: a strategy towards low therapeutic dose
Montanari, D., Chiarparin, E., Gleeson, M. P., Braggio, S., Longhi, R., Valko, K. L., & Rossi, T. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.602968 · Cited by 26
“It is important to note that the recently introduced ligand efficiency (LE) parameters [16,25-26] that relate the in vitro potency to the size (polar surface area, number of heavy atoms) or lipophilicity of the compounds help to optimize the compound’s binding to the target in the most efficient way.”
BackgroundBrouwer, C., Jenko, K. J., Zoghbi, S. S., Innis, R. B., & Pike, V. W. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5007947 · Cited by 28
Lee, S.-Y., Perotti, A., Jonghe, S. D., Herdewijn, P. A., Hanck, T., & Müller, C. E. (2016) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2016.05.046 · Cited by 26
Li, S., Luan, G., Ren, X., Song, W., Xu, L., Xu, M., Zhu, J., Dong, D., Diao, Y., Liu, X., et al. (2015) · Scientific Reports · doi:10.1038/srep14836 · Cited by 29
Spurr, S. S., Bayle, E. D., Yu, W., Li, F., Tempel, W., Vedadi, M., Schapira, M., & Fish, P. V. (2016) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2016.07.041 · Cited by 26
Sanders, J. M., Beshore, D. C., Culberson, J. C., Fells, J. I., Imbriglio, J. E., Günaydin, H., Haidle, A. M., Labroli, M. A., Mattioni, B. E., Sciammetta, N., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01577 · Cited by 29
Lovering, F., Morgan, P. M., Allais, C., AULABAUGH, A. E., Brodfuehrer, J., Chang, J. S., Coe, J. W., Ding, W., Dowty, H. V., Fleming, M. M., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.12.041 · Cited by 26
Leveraging chromatography based physicochemical properties for efficient drug design
Goetz, G. H., & Shalaeva, M. Y. (2018) · ADMET & DMPK · doi:10.5599/admet.529 · Cited by 28
“The LLE/LipE concept has been developed following the introduction of ligand efficiency (LE) [8].”
BackgroundMethodInfluentialaf Rosenschöld, M. M., Johannesson, P., Nikitidis, A., Tyrchan, C., Chang, H., Rönn, R., Chapman, D., Ullah, V., Nikitidis, G., Glader, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00555 · Cited by 26
Couto, M., Alamón, C., Sánchez, C., Dávila, B., Fernández, M., Lecot, N., Cabral, P., Teixidor, F., Viñas, C., & Cerecetto, H. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0060 · Cited by 29
Silva, T., Borges, F., Serrão, P., & Soares-da-Silva, P. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2020.07.015 · Cited by 29
Recent Advances in Lipid-Based Formulation Technology
Porter, C. J. H., Williams, H. D., & Trevaskis, N. L. (2013) · Pharmaceutical Research · doi:10.1007/s11095-013-1229-7 · Cited by 26
“ery candidates suggest that trends towards low water solubility are increasing rather than decreasing (2,3).”
QSAR Modeling and Drug-Likeness Screening for Antioxidant Activity of Benzofuran Derivatives
Boudergua, S., Alloui, M., Belaıdı, S., Mogren, M. M. A., Ibrahim, U. A. A. E., & Hochlaf, M. (2019) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2019.04.004 · Cited by 30
Metadata
- Authors
- Leeson, P. D., & Springthorpe, B.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Leeson, Paul D.
- ORCID
- Leeson, Paul D.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2007-11
- Volume
- 6
- Issue
- 11
- Pages
- 881-890
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2062458432
- Cited by
- 2,403
- References
- 60
- Citations by year
- 2026: 143 · 2025: 113 · 2024: 140 · 2023: 127 · 2022: 104 · 2021: 144 · 2020: 105 · 2019: 146 · 2018: 119 · 2017: 140 · 2016: 145 · 2015: 140 · 2014: 151 · 2013: 160 · 2012: 165
- FWCI
- 6.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- AstraZeneca
- Merck
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Drug Solubulity and Delivery Systems
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- drug-likeness, Lipinski's rule of five, lipophilicity, drug attrition, drug discovery, drug selectivity
- MeSH terms
- Chemistry, Pharmaceutical, Decision Making, Pharmaceutical Preparations, Humans, Water, 1-Octanol
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.